Abstract
We present a study based on density functional theory calculations to explore the rate limiting steps of product formation for oxidation by Flavin-containing Monooxygenase (FMO) and glucuronidation by the UDP-glucuronosyltransferase (UGT) family of enzymes. FMOs are responsible for the modification phase of metabolism of a wide diversity of drugs, working in conjunction with Cytochrome P450 (CYP) family of enzymes, and UGTs are the most important class of drug conjugation enzymes. Reactivity calculations are important for prediction of metabolism by CYPs and reactivity alone explains around 70–85% of the experimentally observed sites of metabolism within CYP substrates. In the current work we extend this approach to propose model systems which can be used to calculate the activation energies, i.e. reactivity, for the rate-limiting steps for both FMO oxidation and glucuronidation of potential sites of metabolism. These results are validated by comparison with the experimentally observed reaction rates and sites of metabolism, indicating that the presented models are suitable to provide the basis of a reactivity component within generalizable models to predict either FMO or UGT metabolism.

















Similar content being viewed by others
Data availability
The data used in the project is available through the referenced publications. The supporting information includes Cartesian coordinates, Z-matrices and total DFT energy values of the presented structures. In addition, the general DFT input files are provided. Code availability: The software used in the project is freely available through the referenced publications.
References
Xu C, Li CY-T, Kong A-NT (2005) Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 28:249–268
Liston HL, Markowitz JS, DeVane CL (2001) Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol 21(5):500–515
Miners JO, Mackenzie PI (1991) Drug glucuronidation in humans. Pharmacol Ther 51(3):347–369
Miners JO, Smith PA, Sorich MJ, Mckinnon RA, Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modelling approaches. Annu Rev Pharmacol Toxicol 44(1):1–25
Tyzack JD, Hunt PA, Segall MD (2016) Predicting regioselectivity and lability of cytochrome P450 metabolism using quantum mechanical simulations. J Chem Inf Model 56(11):2180–2193
Guengerich FP (2006) Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 8(1):101–111
Dixit VA, Lal LA, Agrawal SR (2017) Recent advances in the prediction of non-CYP450-mediated drug metabolism. WIREs Comput Mol Sci 7:1323
Olsen L, Montefiori M, Tran KP, Jørgensen FS (2019) SMARTCyp 3.0: enhanced cytochrome P450 site-of-metabolism prediction server. Bioinformatics 35(17):3174–3175
Cruciani G, Carosati E, BoeckB De, Ethirajulu K, Mackie C, Howe T, Vianello R (2005) MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J Med Chem 48(22):6970–6979
Hennemann M, Friedl A, Lobell M, Keldenich J, Hillisch A, Clark T, Göller A (2009) CypScore: quantitative prediction of reactivity toward cytochromes P450 based on semiempirical molecular orbital theory. ChemMedChem 4(4):657–669
Zaretzki J, Matlock M, Swamidass SJ (2013) XenoSite: accurately predicting CYP-mediated sites of metabolism with neural networks. J Chem Inf Model 53(12):3373–3383
Šícho M, de Bruyn KC, Stork C, Svozil D, Kirchmair J (2017) FAME 2: simple and effective machine learning model of cytochrome P450 regioselectivity. J Chem Inf Model 57(8):1832–1846
Phillips I, Shephard E (2016) Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol 13(2):167–181
Alfieri A, Malito E, Orru R, Fraaije M, Mattevi A (2008) Revealing the moonlighting role of NADP in the structure of a flavin-containing monooxygenase. Proc Natl Acad Sci 105(18):6572–6577
Eswaramoorthy S, Bonanno J, Burley S, Swaminathan S (2006) Mechanism of action of a flavin-containing monooxygenase. Proc Natl Acad Sci 103(26):9832–9837
Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Bélanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, Lancet D, Louisot P, Magdalou J, Chowdhury JR, Ritter JK, Schachter H, Tephly TR, Tipton KF, Nebert DW (1997) The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7(4):255–269
Nair PC, Meech R, Mackenzie PI, McKinnon RA, Miners JO (2015) Insights into the UDP-sugar selectivities of human UDP-glycosyltransferases (UGT): a molecular modelling perspective. Drug Metab Rev 47(3):335–345
Bock KW (2016) The UDP-glycosyltransferase (UGT) superfamily expressed in humans, insects and plants: animal–plant arms-race and co-evolution. Biochem Pharmacol 99:11–17
Mackenzie P, Rogers A, Treloar J, Jorgensen BR, Miners JO, Meech R (2008) Identification of UDP Glycosyltransferase 3A1 as a UDP N-Acetylglucosaminyltransferase. J Biol Chem 283(52):36205–36210
Bosio A, Binczek E, Le Beau MM, Fernald AA, Stoffel W (1996) The human gene CGT encoding the UDP-galactose ceramide galactosyl transferase (cerebroside synthase): cloning, characterization, and assignment to human chromosome 4, band q26. Genomics 34(1):69–75
Banerjee R, Pennington MW, Garza A, Owens IS (2008) Mapping the UDP-glucuronic acid binding site in UDP-glucuronosyltransferase-1A10 by homology-based modelling: confirmation with biochemical evidence. Biochemistry 47(28):7385–7392
Miley MJ, Zielinska AK, Keenan JE, Bratton SM, Radominska-Pandya A, Redinbo MR (2007) Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. J Mol Biol 369(2):498–511
Rendic S, Guengerich FP (2014) Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals. Chem Res Toxicol 28(1):38–42
Krueger SK, Williams DE (2005) Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 106(3):357–387
Fu C-W, Lin T-H (2017) Predicting the metabolic sites by flavin-containing monooxygenase on drug molecules using SVM classification on computed quantum mechanics and circular fingerprints molecular descriptors. PLoS ONE 12(1):e0169910
Guengerich FP (2008) Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21(1):70–83
Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup JR, Ball SE (2004) Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32(11):1201–1208
Sorich MJ, McKinnon RA, Miners JO, Smith PA (2006) The importance of local chemical structure for chemical metabolism by human uridine 5'-diphosphate–glucuronosyltransferase. J Chem Inf Model 46(6):2692–2697
Dang NL, Hughes TB, Krishnamurthy V, Swamidass SJ (2016) A simple model predicts UGT-mediated metabolism. Bioinformatics 32(20):1–7
Mazzolari A, Afzal AM, Pedretti A, Testa B, Vistoli G, Bender A (2019) Prediction of UGT-mediated metabolism using the manually curated MetaQSAR database. ACS Med Chem Lett 10(4):633–638
Lang DH, Rettie AE (2000) In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms. Br J Clin Pharmacol 50(4):311–314
Mushiroda T, Douya R, Takahara E, Nagata O (2000) The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab Dispos 28(10):1231–1237
Rawden HC, Kokwaro GO, Ward SA, Edwards G (2000) Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes. Br J Clin Pharmacol 49(4):313–322
Overby LH, Carver GC, Philpot RM (1997) Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact 106(1):29–45
Hai X, Adams E, Hoogmartens J, Van Schepdael A (2009) Enantioselective in-line and off-line CE methods for the kinetic study on cimetidine and its chiral metabolites with referenceto flavin-containing monooxygenase genetic isoforms. Electrophoresis 30(7):1248–1257
Cashman JR, Park SB, Yang ZC (1993) Chemical, enzymatic, and human enantioselective S-oxygenation of cimetidine. Drug Metab Dispos 21(4):587–597
Taylor KH, Ziegler DM (1987) Studies on substrate specificity of the hog liver flavin-containingmonooxygenase: anionic organic sulfur compounds. Biochem Pharmacol 36(1):141–146
Ottolina G, Gonzalo G, Carrea G (2005) Theoretical studies of oxygen atom transfer from flavin to electron-rich substrates. J Mol Struct (Thoechem) 757(1–3):175–181
Bach R (2011) Role of the somersault rearrangement in the oxidation step for flavin monooxygenases (FMO). A comparison between FMO and conventional xenobiotic oxidation with hydroperoxides. J Phys Chem A 115(40):11087–11100
Hawes EM (1998) N+-Glucuronidation, a common pathway in human metabolism of drugs with a tertiary amine group: 1996 ASPET N-glucuronidation of xenobiotics symposium. Drug Metab Dispos 26(9):830–837
Nishiyama T, Kobori T, Arai K, Ogura K, Ohnuma T, Ishii K, Hayashi K, Hiratsuka A (2006) Identification of human UDP-glucuronosyltransferase isoform (s) responsible for the C-glucuronidation of phenylbutazone. Arch Biochem Biophys 454(1):72–79
Buchheit D, Schmitt EI, Bischoff D, Ebner T, Bureik M (2011) S-Glucuronidation of 7-mercapto-4-methylcoumarin by human UDP glycosyltransferases in genetically engineered fission yeast cells. Biol Chem 392(12):1089–1095
Foti RS, Fisher MB (2005) Assessment of UDP-glucuronosyltransferase catalyzed formation of ethyl glucuronide in human liver microsomes and recombinant UGTs. Forensic Sci Int 153(2–3):109–116
Kuehl GE, Bigler J, Potter JD, Lampe JW (2006) Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes. Drug Metab Dispos 34(2):199–202
Kuehl GE, Murphy SE (2003) N-glucuronidation of nicotine and cotinine by human liver microsomes and heterologously expressed UDP-glucuronosyltransferases. Drug Metab Dispos 31(11):1361–1368
Jin C-J, Miners JO, Burchell B, Mackenzie PI (1993) The glucuronidation of hydroxylated metabolites of benzo [α] pyrene and 2-acetylaminofluorene by cDNA-expressed human UDP-glucuronosyltransferases. Carcinogenesis 14(12):2637–2639
Senafi SB, Clarke DJ, Burchell B (1994) Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 303(1):233–240
Jin C, Miners JO, Lillywhite KJ, Mackenzie PI (1993) Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 264(1):475–479
Yang N, Sun R, Liao X, Aa J, Wang G (2017) UDP-glucuronosyltransferases (UGTs) and their related metabolic cross-talk with internal homeostasis: a systematic review of UGT isoforms for precision medicine. Pharmacol Res 121:169–183
Tukey RH, Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581–616
Li C, Wu Q (2007) Adaptive evolution of multiple-variable exons and structural diversity of drug-metabolizing enzymes. BMC Evol Biol 7(69):1–20
Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, Chowdhury NR, Jansen PLM (1994) Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 269:17960–17964
Fujiwara R, Yokoi T, Nakajima M (2016) Structure and protein–protein interactions of human UDP-glucuronosyltransferases. Front Pharmacol 7:1–15
Lairson LL, Henrissat B, Davies GJ, Withers SG (2008) Glycosyltransferases: structures, functions, and mechanisms. Annu Rev Biochem 77:521–555
Liang D-M, Liu J-H, Wu H, Wang B-B, Zhu H-J, Qiao J-J (2015) Glycosyltransferases: mechanisms and applications in natural product development. Chem Soc Rev 44(22):8350–8374
Locuson CW, Tracy TS (2007) Comparative modelling of the human UDP-glucuronosyltransferases: insights into structure and mechanism. Xenobiotica 37(2):155–168
Ouzzine M, Antonio L, Burchell B, Netter P, Fournel-Gigleux S, Magdalou J (2000) Importance of histidine residues for the function of the human liver UDP-glucuronosyltransferase UGT1A6: evidence for the catalytic role of histidine 370. Mol Pharmacol 58(6):1609–1615
Li D, Fournel-Gigleux S, Barré L, Mulliert G, Netter P, Magdalou J, Ouzzine M (2007) Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem 282:36514–36524
Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI (1999) Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31(4):817–899
Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR (2012) Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminf 4:1–17
Sadowski J, Gasteiger J (1993) From atoms and bonds to three-dimensional atomic coordinates: automatic model builders. J Chem Rev 93(7):2567–2581
Dewar MJS, Zoebisch EG, Healyand EF, Stewart JJP (1985) Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model. J Am Chem Soc 107(13):3902–3909
Stewart JJP (1990) MOPAC: a general molecular orbital package. Quant Chem Prog Exch 10:86
Becke AD (1993) Density-functional thermochemistry. III. The role of exact exchange. J Chem Phys 98:5648–5652
Lee C, Yang W, Parr RG (1988) Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys Rev B 37:785–789
Vosko SH, Wilk L, Nusair M (1980) Accurate spin-dependent electron liquid correlation energies for local spin density calculations: a critical analysis. Can J Phys 58:1200–1211
Stephens PJ, Devlin FJ, Chabalowski CF, Frisch MJ (1994) Ab initio calculation of vibrational absorption and circular dichroism spectra using density functional force fields. J Phys Chem 98(45):11623–11627
Weigend F, Ahlrichs R (2005) Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: design and assessment of accuracy. Phys Chem Chem Phys 7(18):3297–3305
Simón L, Goodman JM (2011) How reliable are DFT transition structures? Comparison of GGA, hybrid-meta-GGA and meta-GGA functionals. Org Biomol Chem 9(3):689–700
Grimme S, Antony J, Ehrlich S, Krieg H (2010) A consistent and accurate ab initio parametrization of density functional dispersion correction (DFT-D) for the 94 elements H-Pu. J Chem Phys 132(15):154104–154119
Valiev M, Bylaska EJ, Govind N, Kowalski K, Straatsma TP, van Dam HJJ, Wang D, Nieplocha J, Apra E, Windus TL, de Jong WA (2010) NWChem: A comprehensive and scalable open-source solution for large scale molecular simulations. Comput Phys Commun 181(9):1477–1489
Lu T, Chen F (2012) Multiwfn: a multifunctional wavefunction analyser. J Comput Chem 33:580–592
Hirshfeld FL (1977) Bonded-atom fragments for describing molecular charge densities. Theor Chim Acta 44:129–138
Leoni C, Buratti F, Testai E (2008) The participation of human hepatic P450 isoforms, flavin-containing monooxygenases and aldehyde oxidase in the biotransformation of the insecticide fenthion. Toxicol Appl Pharmacol 233(2):343–352
Kim Y, Ziegler D (2000) Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase 1. Drug Metab Dispos 28(8):1003–1006
Wu B, Xu B, Hu M (2011) Regioselective glucuronidation of flavonols by six human UGT1A isoforms. Pharm Res 28:1905–1918
Wu B, Zhang S, Hu M (2011) Evaluation of 3,3′,4′-trihydroxyflavone and 3,6,4′-trihydroxyflavone (4′-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1. Mol Pharm 8(6):2379–2389
Kubota T, Lewis BC, Elliot DJ, Mackenzie PI, Miners JO (2007) Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4. Mol Pharmacol 72(4):1054–1062
Laakkonen L, Finel M (2010) A molecular model of the human UDP-glucuronosyltransferase 1A1, its membrane orientation, and the interactions between different parts of the enzyme. Mol Pharmacol 77(6):931–939
Lassila T, Hokkanen J, Aatsinki S-M, Mattila S, Turpeinen M, Tolonen A (2015) Toxicity of carboxylic acid-containing drugs: the role of acyl migration and CoA conjugation investigated. Chem Res Toxicol 28(12):2292–2303
Juovonen R, Rauhamäki S, Kortet S, Niinivehmas S, Troberg J, Petsalo A, Huuskonen J, Raunio H, Finel M, Pentikäinen OT (2018) Molecular docking-based design and development of a highly selective probe substrate for UDP-glucuronosyltransferase 1A10. Mol Pharm 15(3):923–933
Funding
The research was funded by Optibrium Ltd. and Lhasa Ltd.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
MÖ, PAH and MDS are employees of Optibrium Ltd. DJP is an employee of Lhasa Ltd. PJW was an employee of Optibrium Ltd. for the duration of the FMO project.
Ethical approval
The research does not involve human participation or personal data.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Öeren, M., Walton, P.J., Hunt, P.A. et al. Predicting reactivity to drug metabolism: beyond P450s—modelling FMOs and UGTs. J Comput Aided Mol Des 35, 541–555 (2021). https://doi.org/10.1007/s10822-020-00321-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10822-020-00321-1